Not Developing Any New Drugs Could Be EQRx’s Biggest Innovation
The best bet for a new company hoping to deliver on a lofty promise to “remake medicine” could rely on drug repurposing.
Breast Cancer News
BREAST CANCER ADVISOR
Breast Cancer News
Breast Cancer in Women vs Men: Prolonged Survival in Women May Be Influenced by Lead-Time Bias
Recent studies suggest that some misunderstanding around lead-time bias continues to persist in the literature.
Causal Link Suggested for IGF-1 Concentrations, Breast Cancer
In Mendelian randomization analyses, increase in genetically predicted IGF-1 linked to breast cancer.
Patient, Provider Perspectives on Incorporating Prognosis into Shared Decision Making for Women With mBC
In this study, nurse participants emphasized the connection between the early delivery of prognostic information and the optimal delivery of palliative care.
“Medical Distancing” May Help Protect Cancer Patients From Exposure to COVID-19
Screening patients by phone before they come to a clinic may help to eliminate potentially redundant visits and lower the risk of infection.
Breast Cancer Incidence Rising for Young Women Since 1935
Increase began before secular decrease in parity and cannot be attributed to changes in parity over time.
Federal Ruling Puts Pressure on Clinical Trial Sponsors to Post Data
A federal ruling will force trial sponsors to post basic results on ClinicalTrials.gov, but it is unclear whether this is a feasible mandate.
Addition of ICIs to Neoadjuvant Chemotherapy in High-Risk Breast Cancer Supported by Results of Phase 3 Trial
Results of earlier-phase trials provided support for this phase 3 trial in triple-negative, stage II/III breast cancer.
Many Young Women With Breast Cancer Experience Financial Decline
Common concerns among employed respondents include increased time off, suffering job performance.
First Human Clinical Trial in US to Test the Use of CRISPR-Modified T Cells in Cancer Answers Vital Questions
CRISPR-modified T cells were used in 3 patients with advanced cancer for the first time, showing modest results on tumor growth.
Improving Cancer Pain Management Amid the Opioid Crisis
Research into opioid alternatives for cancer-related pain has stalled, however substance use disorders remain problematic.
A New Trend in Drug Development: Leveraging Data from Expanded Access
Drug companies are gathering and including expanded access data in drug submissions as real-world data, but the purpose of expanded access was never for the purpose of research.
Addition of Immunotherapy to Standard Neoadjuvant Chemotherapy Yields Promising Results in HER2-Negative Breast Cancer
The adaptive design of the I-SPY2 study allowed for the rapid evaluation of novel drugs in combination with neoadjuvant chemotherapy (NAC) compared with NAC alone.
Continuing Annual Breast Cancer Screening No Benefit in Over-75s
No significant reductions found in eight-year breast cancer mortality for continuing versus stopping screening.
Evidence Suggests B Cells Play a Role in Immunotherapy Response
New research shows that B cells — and not just T cells — influence whether patients respond to immunotherapy in melanoma, sarcoma, and kidney cancers.
Adding Tucatinib Improved PFS, OS in Metastatic HER2+ Breast Cancer
Survival benefits were maintained among those with brain metastases.
The Questionable Practice That Permeates Oncology Clinical Trials
Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.
Tucatinib Gets Priority Review for Locally Advanced or Metastatic HER2-Positive Breast Cancer
The FDA has accepted for Priority Review the New Drug Application (NDA) for tucatinib (Seattle Genetics), in combination with trastuzumab and capecitabine, for the treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received at least 3 prior HER2-directed agents separately or in combination, in the neoadjuvant, adjuvant or metastatic setting.
Integrative Oncology: Using Evidence-Informed Medicine to Improve Patient Outcomes and Quality of Life
Lifestyle-based integrative treatment approaches — deemed scientifically sound by the field’s proponents — merge conventional and complementary treatments.
High BMI May Cut Overall Survival in HER2+ Metastatic Breast Cancer
BMI had no impact on progression-free survival to first-line chemotherapy.
Want to read more?
Please login or register first to view this content.
Next post in Breast Cancer News
